NCT03383276

Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of Interleukin-1-Receptor Antagonist will be assessed.

Conditions

• Blepharokeratoconjunctivitis

Interventions

Type	Name	Description
DRUG	IL-1Ra	custom eye drop to be applied to the left eye.

Timeline

• Start date: 2017-12-18
• Primary completion: 2018-03-25
• Completion: 2018-06-10
• First posted: 2017-12-26
• Last updated: 2017-12-26

Locations

1 site across 1 country: China